UK’s NICE Rejects Use Of Orexigen’s Mysimba For Obesity

08:07 EDT 1 Aug 2017 | SCRIP

Consilient, which markets Orexigen’s obesity drug Mysimba in the UK and Ireland, says it is “extremely disappointed” by NICE’s decision...


Related Stories


Original Article: UK’s NICE Rejects Use Of Orexigen’s Mysimba For Obesity


More From BioPortfolio on "UK’s NICE Rejects Use Of Orexigen’s Mysimba For Obesity"

Quick Search

Relevant Topics

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...